Elsevier, the global information analytics business specialising in science and health, has announced that six start-up companies have been selected from more than 150 global applicants for The Hive, Elsevier's innovation initiative for biotech and pharmaceutical start-ups.
Exscientia, LegoChem Biosciences, 4P-Pharma, Beacon Discovery, Sigilon Therapeutics, and Unum Therapeutics, were selected for their commitment to cutting-edge science in emerging areas of research. All six demonstrate significant potential to impact how future treatments are researched and developed. As members of The Hive, each company will receive support, complimentary training, and access to Elsevier's suite of information solutions for 18 months.
The goal of The Hive is to help foster the discoveries that happen in these early stages, start-up environments, ensuring that the route to market for new innovations is accelerated. The six participating companies - the second intake of start-ups to The Hive - will use Elsevier's tools to support their innovative work in some of the hottest research areas.
Elsevier's suite of R&D Solutions fuels research and decision-making in early stage drug discovery and development, and are used by most of the world's leading biopharmaceutical companies. The products that The Hive participants will be using include: Pathway Studio™, Reaxys®, Reaxys® Medicinal Chemistry, ScienceDirect, Scopus, PharmaPendium®, and Embase®. The Hive, which first launched in 2016 with four start-ups selected to take part, engages the global pharma community via content featuring the participants, which will be widely-promoted throughout Elsevier's online and social networks.
Brought to you by Scope e-Knowledge Center, a trusted global partner for digital content transformation solutions - Abstracting & Indexing (A&I), Knowledge Modeling (Taxonomies, Thesauri and Ontologies), and Metadata Enrichment & Entity Extraction.
